Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 12
Submit an article Journal homepage
4,116
Views
8
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

Margaret E. GerbasiPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Daniel StellatoPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Sameer R. GhateNovartis Pharmaceuticals Corp, East Hanover, NJ, USA;
,
Briana NdifeNovartis Pharmaceuticals Corp, East Hanover, NJ, USA;
,
Aaron MoynahanPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Dinesh MishraNovartis Pharmaceuticals Corp, Hyderabad, India
,
Praveen GundaNovartis Pharmaceuticals Corp, Hyderabad, India
,
Roy KoruthNovartis Pharmaceuticals Corp, Hyderabad, India
&
Thomas E. DeleaPolicy Analysis Inc. (PAI), Brookline, MA, USA; Correspondence[email protected]
 show all
Pages 1243-1252 | Received 20 Mar 2019, Accepted 20 Jun 2019, Published online: 04 Aug 2019

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

P. Petrou. (2019) Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma . Journal of Medical Economics 22:12, pages 1241-1242.
Read now

Articles from other publishers (7)

Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang & Yun Lu. (2023) Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41:3, pages 295-306.
Crossref
Huiling Piao, Meiyu Wu, Shuxia Qin, Zhiyao Tang, Guangliang Zhou, Xiaomin Wan & Xiaocong Zuo. (2023) Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis. Gynecologic Oncology 168, pages 17-22.
Crossref
Steffen Wahler, Alfred Müller, Sabine Fuchs & Johann-Matthias von der Schulenburg. (2022) Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. Health Economics Review 12:1.
Crossref
Emily Z Ma, Julia H Terhune, Zafar Zafari, Kyle W Blackburn, John A Olson, C Daniel Mullins & Yinin Hu. (2022) Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. Journal of the American College of Surgeons 234:4, pages 521-528.
Crossref
Saam A. Mojtahed, Nicole R. Boyer, Saieesh A. Rao, Thomas F. Gajewski, Jennifer Tseng & Kiran K. Turaga. (2021) Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals of Surgical Oncology 28:13, pages 9039-9047.
Crossref
Bin Wu & Lizheng Shi. (2020) Frontline BRAF Testing–Guided Treatment for Advanced Melanoma in the Era of Immunotherapies . JAMA Dermatology 156:11, pages 1177.
Crossref
Justine V. Cohen & Elizabeth I. Buchbinder. (2019) The Evolution of Adjuvant Therapy for Melanoma. Current Oncology Reports 21:12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.